Rate My Professor Orazio Vittorio
Ratings & reviews
Fosters collaboration and teamwork. Sometimes methodologies and hypothesis for student projects are a bit bias. Students only tend to publish one research paper as first author in PhD period and it usually will be published well after finishing. He will give a lot of support and positive energy to get finished.
A true inspiration to all learners.
Encourages students to think independently.
This comment is not public.
Taught by or worked with Orazio?
Add your rating. It takes about 30 seconds.
About Orazio
Associate Professor Orazio Vittorio is a Scientia Associate Professor in the School of Biomedical Sciences within the Faculty of Medicine & Health at the University of New South Wales (UNSW) in Sydney. He earned a Master of Science in Biology in 2006 and a PhD in Oncology in 2011. As Team Leader at the Children’s Cancer Institute and Head of the Metal Targeted Therapy & Immunology lab, Vittorio is an internationally recognized cancer biologist specializing in the mechanisms of anti-cancer therapeutics in paediatric cancers. His research investigates copper metabolism and homeostasis in aggressive childhood malignancies, including neuroblastoma, low-grade glioma, diffuse midline glioma (DIPG), and glioblastoma. Key areas encompass copper-targeted anticancer drugs, their impact on tumour immunity, cancer immunology, single-cell transcriptomics, nanomedicine, and PET imaging protocols using radiolabelled copper to monitor therapy response.
Vittorio has authored over 100 peer-reviewed journal articles and six book chapters, holding inventorship on six patents. Notable publications include "Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion" (Cancer Research, 2020), "Copper chelation redirects neutrophil function to enhance anti-tumour immunity" (Nature Communications, 2024), "A novel network-based method identifies a cuproplasia-related pan-cancer gene signature to predict patient outcome" (Human Genetics, 2024), and "Copper: An intracellular Achilles heel allowing the targeting of epigenetics, kinase pathways and cell metabolism in cancer therapeutics" (MedChemComm, 2021). His pioneering discoveries reveal elevated copper levels in neuroblastoma cells compared to normal cells, copper's role in immune evasion by neuroblastoma and gliomas, and the potential of copper chelation as an epigenetic therapy and immunotherapy booster. Over the past decade, he has secured more than $5 million in competitive funding as Chief Investigator and over $10 million as co-investigator, including NHMRC Career Development Fellowships and UNSW Scientia Fellowship (2019-2026). Awards include Cancer Institute NSW Outstanding Career Development Fellow of the Year (2020), Young Tall Poppy Science Award (2021), Cure Cancer Australia Research of the Year (2022), UNSW Postgraduate Research Supervisor Award (2018), and Early Career Researcher Best Publication Award (2018). His positions at UNSW, Children’s Cancer Institute, and Kids Cancer Alliance advance translation of copper-targeting strategies to clinical settings.
Trending Research & Publication News
SPARC Cost of Knowledge Study: 95% Public Investment in Articles
Photo by Precondo CA on Unsplash
AI Research Scooping: OpenAI & Anthropic Priority Disputes
Photo by Brecht Corbeel on Unsplash
Informa Taylor & Francis Split & Clarion Deal | AcademicJobs
Photo by Anne Nygård on Unsplash
arXiv Two-Submission Monthly Cap Explained | AcademicJobs
Photo by Kelly Sikkema on Unsplash
Cell Press Bribery Investigation: Cancer Cell Editor Accused
Photo by Markus Winkler on Unsplash
Society Journal Sales & Nonprofit Consolidations | AcademicJobs
Photo by Philip Strong on Unsplash